Gene Editing Breakthroughs Demand a New Approach to Healthcare

Gene editing advancements hold remarkable potential for addressing rare genetic disorders, but they come with significant challenges that require a rethinking of how healthcare is structured. A small fraction of the approximately 20,000 human genes can lead to diseases when disrupted, resulting in thousands of rare disorders. Unlike common conditions such as type 2 diabetes, where treatment options like metformin are widely available, many genetic mutations affect only a handful of individuals globally. This complicates the development of effective treatments, as doctors often lack knowledge about specific mutations and their remedies.

Recent breakthroughs in gene editing are garnering significant attention. However, the path from laboratory innovation to patient treatment is fraught with difficulties. According to Brian David Smith in his analysis titled New Drugs, Fair Prices, the average cost of bringing a new drug to market is approximately $2 billion. This expense is partly due to the low success rate for drugs transitioning from discovery to market, with only a fraction of the nearly 8,000 diseases affecting humans having approved treatments.

The financial landscape of biotechnology tends to favour lucrative markets, particularly cancer therapies, while treatments for rare genetic disorders are often viewed as too costly to pursue. For example, a groundbreaking gene therapy developed in 2022 at Great Ormond Street Hospital (GOSH) in London targeted a young patient suffering from relapsed T-cell leukaemia. Dr. Waseem Qasim, a leading paediatric immunologist at GOSH, cautioned that while effective treatments are emerging, they may not be financially viable for widespread adoption.

The sustainability of innovative healthcare solutions cannot rely solely on philanthropic efforts. For instance, Dr. Qasim’s development of “off-the-shelf” edited T-cells necessitates industrial-scale production to ensure accessibility, yet the current market dynamics do not support such a model. The research conducted at GOSH illustrates both the promise and the limitations of current therapies. As investment in biotechnology shifts toward more profitable sectors like artificial intelligence, critical advancements in gene editing face uncertain futures.

A recent milestone in gene editing came from Prime Medicine, which achieved success in treating a teenager with a rare immune disorder. However, the company announced it would halt future projects, highlighting the precarious environment for cutting-edge research. Additionally, the geopolitical landscape for pharmaceutical companies is evolving, with many firms relocating their research and manufacturing operations to countries like China and the United States, where long-term policy support is more robust.

The United Kingdom finds itself in a vulnerable position, particularly following Donald Trump’s administration, which pressured the UK into accepting higher prices for National Health Service (NHS) medications under the threat of tariffs. This situation compromises funding for patient care and innovative therapies. The per-patient costs of gene therapies can reach into the six or seven figures, making it imperative to reassess existing business models.

To truly harness the potential of gene therapy, the UK needs a state-backed manufacturing framework to ensure medical sovereignty. The reality remains that nations like China can produce certain gene therapies at significantly lower costs, raising questions about how the UK can remain competitive in this field.

A renewed social contract is essential for fostering innovation that benefits the public rather than being sequestered for profit. Approaching rare-disease gene therapy as a collective service, similar to dialysis or organ transplants, could provide a solution. This model would treat gene therapies as NHS services funded collectively, rather than as commodities.

Many experimental treatments could continue through NHS research programmes, offered at cost while scientific understanding evolves. A comprehensive, publicly funded health system that guarantees equitable access and lifelong patient follow-up is crucial in transforming gene therapy into a common good rather than a market-driven product. Without the support of the NHS and charitable organizations, groundbreaking therapies risk remaining confined to research laboratories, with their potential unrealized.